InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,699.94
(
-0.17%
)
US TECH 100
19,240.00
(
-0.20%
)
Dow Jones
42,011.59
(
-0.44%
)
Brent Oil
77.73
(
4.17%
)
Bitcoin
60,848.33
(
0.37%
)
Post# of 253271
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120524
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 225979

Monday, 05/09/2022 11:01:11 AM

Monday, May 09, 2022 11:01:11 AM

Post# of 253271
OXUR.BR -43% on phase-2 failure in DME:

https://finance.yahoo.com/news/oxurion-announces-top-line-results-063000823.html

The Part A data showed THR-687 to be safe and well tolerated with no serious adverse events and none of the patients required rescue medication through Month 3, however, there was insufficient evidence of efficacy on the key endpoints (Best-Corrected Visual Acuity and Central Subfield Thickness). As a result, Oxurion has decided not to advance THR-687 to Part B of the INTEGRAL trial.

In other words, the DME program is kaput. A prior phase-2 trial in the same indication failed in 2019 (#msg-150629948).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up